Paying for precision

Up close with cancer: Why Mitra Biotech is looking to Nasdaq

In 10 years and with just $36 million, Mitra has built what could transform cancer care. It’s looking to Nasdaq to unlock its value, and to India to pressure-test its technology

12/03/18

Seema Singh

Cancer treatment today wades through diagnostics, each with high claims. But they often provide little value in most cancers and to a vast majority of patients. Mitra Biotech is out to break the mould

Providing a definitive choice to the doctor, it claims to cut not just pharmaco-toxicity but also economic toxicity rampant in this disease

It may have flipped its corporate structure for a possible Nasdaq listing, its challenges seem unenviable, at least to its competitors

By early next year, it plans to show the world why payers should pay attention. Better, fully reimburse its tests

rifle-2577885_1920-1920x1280.jpg

Want to read a free 200 word summary?

Create an account

Sometime in mid-2015, a young cancer patient in New York City was driven to desperation. The family had built a treatment war chest of a few million dollars but the drugs weren’t working. None at all. Not even Keytruda, the expensive breakthrough drug from Merck & Co. which was approved around that time. Through academic…

To access this post, you must purchase Monthly Recurring, Quarterly or Weekly Product.

Read the full story. Subscribe to Premium.

Or subscribe. Why? Let us explain.

Subscribe now

Already Registered?

Related stories

More stories in /Healthcare & /Technology

See all in Analysis & Technology

This story is for subscribers only.
Subscribe or Log In

Read the full story. Subscribe now.

Or subscribe. Why? Let us explain.

The selected story is available only for paid subscribers. Might want to change your mind!

Subscribe now

Already Registered? Login

Questions?

What is The Ken?

The Ken is a subscription-driven media site. We write one story a day (weekdays only). These stories have sharp, original insights on technology, business, science and healthcare from India.

Why do I have to sign up to read your stories?

Our stories are not free. Well, some select stories are. But, a significant part of what we write at The Ken is for subscribers only. We put in a lot of effort and resources in writing our stories and believe that you must pay for good journalism.
Hence, our three plans. 1) The annual membership
2) The free sign up
3) The recurring quarterly subscription

On journalism and why you should pay for it, if you haven’t already seen it, here’s a great explainer from John Oliver.

So, one must pay for journalism?

Yes.

How many stories will I get if I take an annual membership?

200+ stories.

And, in the free sign up?

Four stories every month.

Do I get a refund?

We allow you to sample our journalism for free before signing up, and after you do, we stand by its quality. But we do not offer refunds.

I am not getting my daily emails. Do I have to whitelist emails from The Ken?

An added benefit of your subscription (free/paid) are the daily personalised emails. These emails, at times, might end up in your spam/junk folder due to emojis, attachments or images. In case you’re not receiving these emails, it might help to whitelist us. If the problem still persists, write to us at [email protected].

Why am I unable to access the archives?

Full and unrestricted access to our archives is a feature of our annual membership.

My payment is not going through, what can I do?

Please write to us at [email protected] detailing the payment error or queries.

See all FAQs

    See all results for Ken

    No results found for Ken.